Page last updated: 2024-10-27

gliclazide and Hepatitis B Virus Infection

gliclazide has been researched along with Hepatitis B Virus Infection in 1 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Research Excerpts

ExcerptRelevanceReference
"Rosiglitazone plus SU was well tolerated irrespective of hepatitis B and C serological status."6.71Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. ( Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX, 2003)
"Rosiglitazone plus SU was well tolerated irrespective of hepatitis B and C serological status."2.71Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. ( Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX, 2003)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhu, XX1
Pan, CY1
Li, GW1
Shi, HL1
Tian, H1
Yang, WY1
Jiang, J1
Sun, XC1
Davies, C1
Chow, WH1

Trials

1 trial available for gliclazide and Hepatitis B Virus Infection

ArticleYear
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
    Diabetes technology & therapeutics, 2003, Volume: 5, Issue:1

    Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther

2003